Similarly, breast cancers high in CCNE2 had worse overall survival (Figure 2E), and a trend towards worse overall survival if they had not undergone genome doubling (Figure 2F), but not in those breast cancers which were genome doubled (Figure 2G). This evidence concerns the gene CCNE2 and breast carcinoma.